Articles tagged with Adenocarcinoma
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
Researchers discovered that degrading mutant KRAS protein leads to greater lung cancer regression and more durable antitumor responses than conventional inhibitors. The study also identifies resistance mechanisms distinct from those previously described, offering new insights into targeted protein degradation therapies.
The BiliSeq test detected approximately 82% of bile duct cancers, compared to 44% with pathology alone, and increased cancer detection to nearly 90% when combined with pathology. This improved accuracy enables physicians to provide more personalized medicine and treatment options for patients.
This study investigates the clinicopathologic features and genomic landscape of DNA polymerase epsilon mutant colorectal adenocarcinomas. The analysis reveals two distinct subgroups with different outcomes, suggesting improved prognostication for some patients.
A new consensus classifier for pancreatic cancer has been developed, enabling accurate determination of tumor subtypes and informing treatment choices. The tool also identifies risk factors for the disease, including smoking, which may be more significant in certain subtypes.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
Lung cancer subtypes differ in metabolic profiles, with metabolomics offering insights into subtype-specific alterations. Metabolomics enables effective subtype differentiation and identification of potential biomarkers for early diagnosis and personalized therapy.
A new study in The American Journal of Pathology reveals that perilipin 2 protein modulates aggressive cancer progression in advanced lung adenocarcinoma by regulating lipid droplet accumulation. High perilipin 2 expression is associated with more aggressive disease progression and shorter recurrence-free survival times.
A new study highlights the potential of natural Gal-3 inhibitor, modified citrus pectin, to restore treatment efficacy in pancreatic cancer. Gal-3 inhibition in combination with gemcitabine reduces tumor growth and reverses drug resistance.
A new study found a sharp increase in appendix cancer incidence rates for those born after 1945, particularly among Generation X and Millennials. The researchers estimated age-specific incidence rates of appendiceal adenocarcinoma per 100,000 persons between 1975 and 2019.
The study found an increase in pancreatic adenocarcinoma among all age groups, while a notable rise was observed in colorectal adenocarcinoma among younger patients. This trend highlights the importance of early detection and evaluation for clinicians when evaluating patients with relevant symptoms.
Researchers found significant disparities in quality of care and outcomes for patients with metastatic pancreatic cancer. Patients with higher social vulnerability indices were less likely to receive guideline-concordant systemic therapy, palliative care, or survive over 12 months.
High IARS2 expression in PDAC tissues correlates with poor prognosis, promoting cell proliferation, migration, and invasion via upregulation of EMT transcription factors. IARS2 stabilizes β-catenin and activates the WNT/β-catenin pathway, creating an immunosuppressive microenvironment.
Researchers found that added sugars contribute between 7% and 21% to the risk of gastric cancer, while sodium intake is the main mediating factor. Healthy diets characterized by high vegetable and fruit consumption can reduce this risk.
Researchers studied the prognostic power of micropapillary patterns in PDAC, finding that even small percentages serve as independent prognostic factors for decreased survival. The study suggests incorporating micropapillary pattern percentage into pathology reports could enhance patient management strategies.
A genetic fault long believed to drive oesophageal cancer development may actually play a protective role early in the disease, according to new research. The study found that defects in CDKN2A were more common in people with Barrett's oesophagus who never progressed to cancer.
Researchers developed a deep learning model that classifies pancreatic cancer into molecular subtypes using histopathology images, achieving high accuracy and rapid turnaround time. The AI tool has the potential to improve patient outcomes by enabling timely and tailored treatment strategies.
A new study suggests that MRI can predict patient outcomes and the risk of tumor reccurrence or spread for patients with rectal cancer who have undergone chemotherapy and radiation. This information could help doctors determine the best course of treatment, including whether to spare patients from invasive surgery.
A multicenter study found that specific KRAS mutations in pancreatic cancer can affect patient outcomes, with some variants associated with better overall survival. The research suggests revising clinical guidelines to recommend routine molecular testing in all patients with pancreatic cancer.
Researchers found that Brusatol increases Gem's effectiveness against pancreatic ductal adenocarcinoma by suppressing Nrf2 signaling. The study also showed that combining Brusatol with Nrf2 silencing significantly enhanced Gem's efficacy in vitro and in vivo.
The study identified RNF144B as a tumour suppressor that prevents genomic instability, but low expression leads to poor prognosis and treatment resistance in lung adenocarcinoma. The research suggests that even non-mutated genes like RNF144B can have a significant impact on cancer development.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
A new AI tool developed by NYU Langone Health accurately diagnoses adenocarcinoma lung cancer and predicts its severity and likelihood of return. The tool uses histomorphological features to distinguish between similar lung cancers and predict tumor recurrence with 99% accuracy.
A new study from Umeå University found that lung cancer rates haven't decreased as expected with reduced smoking. Despite declining smoking rates, the number of cases of lung cancer has increased, especially among women. The study suggests that previous assumptions about the quick decrease in risk after quitting may have been exaggerated.
Research reveals a significant connection between oral bacteria and accelerated pancreatic cancer development in mice. Viable Porphyromonas gingivalis was found in the pancreas of healthy mice after gum application, causing changes in the organ's microbial balance.
A new atlas of lung cells reveals transitional alveolar cell state harboring KRAS mutations in normal lung cells, which can lead to lung adenocarcinoma. This finding opens doors for developing new detection strategies.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
Researchers propose a novel augmentation regimen, IPIAD, combining five generic non-oncology drugs with standard chemotherapy for pancreatic ductal adenocarcinoma. The IPIAD regimen uses repurposed drugs like irbesartan and azithromycin to potentially slow disease growth and improve outcomes.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
A team of researchers at Mays Cancer Center has identified protein markers that could signal the early development of metastatic lung cancer. These markers have led to a $1.6 million grant and will pave the way for a clinical trial in patients with advanced lung cancer.
Researchers developed a reliable and reproducible real-time live tissue sensitivity assay (RT-LTSA) using fresh tumor samples to predict patients' clinical response to chemotherapy. The study showed improved disease-free survival and reduced recurrence rates in patients who received RT-LTSA sensitive adjuvant regimens.
Researchers have discovered two FDA-approved and EMA-approved drugs that inhibit prmt5, a protein linked to promoting tumor growth in several cancers. These repurposed drugs show promise in reducing cancer cell proliferation and tumor growth.
A large international database analysis found nearly a quarter of esophageal adenocarcinoma patients had normal endoscopies but were still diagnosed within a year. The study suggests using high-quality equipment, rigorous sampling protocols, and future research on biomarker panels to improve screening effectiveness.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers discovered that air pollution particles trigger autophagy, a cellular defense process, which has an upper threshold and may reduce its effectiveness against other threats. This finding provides new insights into the link between air pollution and lung disease.
A retrospective study found that elevated CA 19-9 and CEA levels were associated with worsened outcomes in duodenal adenocarcinoma patients. The study, which included 68 patients, suggests that these tumor markers may show promise as prognostic tools for this rare malignancy.
The study found that downregulation of angulin-1/LSR leads to increased claudin-2 expression and altered cell metabolism in human lung adenocarcinoma cells, promoting malignancy. Researchers identified AG1478 and EW-7197 as potential therapeutic agents.
Researchers have found that valosin-containing protein (VCP) is essential for KRAS-mutant pancreatic ductal adenocarcinoma cell growth and survival. Inhibiting VCP, combined with autophagy inhibition, enhances efficacy in preclinical studies.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Researchers at MUSC Hollings Cancer Center discovered the cellular origin of normal pancreatic fibroblasts and cancer-associated fibroblasts, which play a key role in tumor progression. The findings suggest that targeting cancer-associated fibroblasts holds exciting potential for therapeutic benefits.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
A study by University of Barcelona researchers has identified TIMP-1 as a key player in the progression of non-small cell lung cancer, a subtype of adenocarcinoma. Elevated levels of TIMP-1 from fibroblasts can cause increased tumor proliferation and invasion when interacting with CD63 receptors on cancer cells.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
A study has found that patients with pancreatic ductal adenocarcinoma (PDAC) are six times more likely to have had gallstone disease within the year prior to diagnosis than non-cancer patients. This association suggests that gallstones could be a warning sign for this aggressive and deadly cancer.
Research found a significant increase in esophageal cancer and Barrett's esophagus among middle-aged adults, with rates nearly doubling between 2012 and 2019. The study suggests an urgent need for earlier endoscopic screening in this age group, particularly those with multiple risk factors.
Adults aged 45-64 experienced a nearly doubled rate of esophageal cancer and a 50% increase in Barrett's esophagus between 2012 and 2019. Researchers recommend more frequent screening for middle-aged patients with multiple risk factors.
Research suggests gallstone disease may be an early indicator of pancreatic cancer, with patients having gallstones nearly six times more likely to develop the disease. This association could lead to earlier diagnosis and treatment, potentially improving survival rates for pancreatic cancer patients.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.
Researchers have discovered that cancer cells carrying a common mutation accumulate large amounts of ferrous iron, which can be exploited to deliver powerful anticancer drugs. The therapeutic strategy could treat various cancers driven by KRAS mutations.
A study analyzing US SEER data from 2000-2016 found that younger age groups experienced the steepest increase in distant-stage early-onset colorectal adenocarcinoma incidence. Younger non-Hispanic Black and Hispanic populations showed greater proportions of distant-stage disease.
The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.
A recent study by NTU Singapore has found a strong link between increasing air pollution and the rise of lung adenocarcinoma, a type of cancer. The study also discovered that declining smoking rates are associated with lower incidence of lung squamous cell carcinoma.
A new study finds oesophageal cancer cases have tripled in under 50s, with increases attributed to lifestyle-related risk factors such as smoking and poor diet. The study also shows improved relative survival rates for younger patients, highlighting the importance of early diagnosis and treatment.
Researchers discovered RNA editing events in lung adenocarcinoma and identified a new molecular subtype EC3 with the poorest prognosis. A simplified prediction model using eight RNA editing sites accurately distinguishes this subtype, which is associated with sensitivity to specific chemotherapy drugs.
A recent study across 40 countries found higher lung cancer rates in young women compared to men, driven by a rise in adenocarcinoma. Historically, lung cancer was more prevalent among men due to earlier smoking habits, but the gap is narrowing in some regions.
A study published in the American Journal of Roentgenology found that fluorodeoxyglucose PET, combined with high-resolution CT, can predict invasive histopathologic subtypes of early lung adenocarcinoma. The imaging technique also showed higher SUVmax values in invasive adenocarcinomas compared to non-invasive forms.
Researchers at Mayo Clinic have identified two distinct pathways for lung adenocarcinoma development, which can inform treatment strategies and predict patient response. The study's findings suggest that targeting specific pathways may provide alternative treatment options for patients with limited response to traditional therapies.